Cost-effectiveness analysis of routine rotavirus vaccination in Brazil

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 23, Issue 4, 2008, Pages 221-230

  De Soârez, Patrícia Coelho ^a   Valentim, Joice ^a   Sartori, Ana Marli Christovam ^a   Novaes, Hillegonda Maria Dutilh ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Brazil; Cost effectiveness analysis; Rotavirus vaccines

Indexed keywords

COST-BENEFIT ANALYSIS; DISEASE INCIDENCE; DISEASE SEVERITY; HEALTH CARE; INFECTIOUS DISEASE; SENSITIVITY ANALYSIS; VACCINATION; VIRAL DISEASE; VIRUS;

BRAZIL; SOUTH AMERICA;

ROTAVIRUS;

EID: 44449090130     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/s1020-49892008000400001     Document Type: Article

References (29)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565-72.
2. Ruiz-Palados GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New Engl J Med. 2006;354(1):11-22.
3. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent humanbovine (WC3) reassortant rotavirus vaccine. New Engl J Med. 2006;354(1):23-33.
4. Glass RI, Parashar UD. The promise of new rotavirus vaccines. New Engl J Med. 2006; 354(1):75-7.
5. Sastry N, Burgard S. The prevalence of diarrheal disease among Brazilian children: trends and differentials from 1986 to 1996. Soc Sci Med. 2005;60(5):923-35.
6. Linhares AC. Rotavirus infection in Brazil: epidemiology and challenges for control. Cad Saúde Pública. 2000;16(3):629-46.
7. Brasil, Ministério da Saúde, DATASUS, Informaç ões de Saúde [Internet site]. Available from: http://tabnet. datasus.gov.br/cgi/ tabcgi. exe?pni/cnv/DPniuf.def. Accessed 9 January 2006.
8. Smith JC, Haddix AC, Teutsch SM, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics. 1995;96(4):609-15.
9. Tucker AW, Haddix AC, Bresee JS, Holman RC, Parashar UD, Glass RI. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA. 1998;279(17): 1371-6.
10. Carlin JB, Jackson T, Lane L, Bishop RF, Barnes GL. Cost-effectiveness of rotavirus vaccination in Australia. Aust N Z J Public Health. 1999;23(6):611-6.
11. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis. 2005;192(suppl 1): S133-45.
12. Fisher TK, Ann DD, Antil L, Cat ND, Kilgore PE, Thiem VD, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis. 2005;192(10):1720-6.
13. Constenla D, O'Ryan M, Navarrete MS, Antil L, Rheingans RD. Evaluación de costo-efectividad de la vacuna anti-rotavirus en Chile. Rev Med Chile. 2006;134(6):679-88.
14. Rheingans RD, Constela D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica. 2007;21(4):205-16.
15. Berger ML, Murray JF, Xu J, Pauly M. Alternative valuations of work loss and productivity. J Occup Environ Med. 2001;43(1):18-24.
16. World Health Organization. Making choices in health: WHO Guide to Cost-Effectiveness Analysis. Geneva: WHO; 2003.
17. Brasil, Instituto Brasileiro de Geografia e Estatística [Internet site]. Available from: http://www.ibge.gov.br. Accessed 15 November 2006.
18. Sartori AMC, Valentim J, de Soárez PC, Novaes HM. Rotavirus morbidity and mortality in children in Brazil. Rev Panam Salud Publica. 2008:23(2):92-100.
19. Velazquez FR, Matson DO, Calva JJ, Guerrero ML, Morrow AL, Carter-Campbell S, et al. Rotavirus infection in infants as protection against subsequent infections. New Engl J Med. 1996;335(14):1022-8.
20. Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infec Dis. 2002;34:1351-61.
21. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis. 2005;192(suppl 1): S36-43.
22. Salinas B, Schael IP, Linhares AC, RuizPalacios GM, Guerrero ML, Yarzábal JP, et al. Evaluation of safety, immunogenidty and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J. 2005;24(9):807-16.
23. Brasil, Ministério da Saúde, DATASUS, Informaç ões de Saúde [Internet site]. Available from: http://w3.datasus. gov.br/datasus/ datasus.php. Accessed 9 January 2006.
24. Brasil, Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional por Amostra de Domicílios [Internet site]. Acesso e utilização de serviços de sa-de-2003. Available from: http://www.ibge.gov.br/home/estatistica/ populacao/trabalhoerendimento/pnad2003/ saude/default.shtm. Accessed 3 January 2007.
25. Koopmanschap MA, Rutten F. A practical guide for calculating indirect costs of disease. Pharmacoeconomics. 1996;10(5):460-6.
26. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
27. World Health Organization. CHOosing Interventions that are Cost-Effective (WHOCHOICE). Cost-effectiveness thresholds [Internet site]. Available from: http://www.who.int/choice/costs/CER_ thresholds/en/ index.html. Accessed 29 January 2007.
28. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Pública. 2007; 21(4):192-204.
29. Brasil, Instituto Brasileiro de Geografia e Estatística, Sistema de Contas Nacionais [Internet site]. Available from: http://www.ibge. gov.br/home/estatistica/economia/contas nacionais/referencia2000/2005/default. shtm. Accessed 7 November 2007.